We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Granulocyte Macrophage-Colony Stimulating Factor Protects Mice from the Flu

By LabMedica International staff writers
Posted on 05 May 2011
A study conducted on several different populations of mice found that that pulmonary administration of granulocyte macrophage-colony stimulating factor (GM-CSF) significantly reduced flu symptoms and prevented death after challenge with a lethal dose influenza virus.

GM-CSF protein is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. More...
Alveolar macrophages (AM), which are enhanced by GM-CSF, are essential to the innate immune response and have been shown to contribute to host defense against flu infections in various animal models.

In the current study, investigators at the University of Texas Health Science Center (Tyler, USA) worked with three groups of mice: a normal wild type control group, a line that had been genetically engineered to lack the gene for GM-CSF, and a line that had the GM-CSF gene in one lung only. Animals from each group were infected with influenza virus in an initial series of experiments.

Results published in the April 7, 2011, online edition of the American Journal of Respiratory and Critical Care Medicine revealed that after progressive weight loss, all the wild type and GM-CSF null mice died within days. In contrast, all the mice carrying the GM-CSF gene survived, and these animals gained back the weight they had initially lost after a short period of time. The resistance of the transgenic mice to influenza was canceled by elimination of alveolar macrophages, but not by depletion of T-cells, B-cells, or neutrophils.

In a second series of experiments, animals were given GM-CSF after having been infected with the flu virus. Delivery of intranasal GM-CSF to the wild type mice conferred resistance to influenza to these animals. This resistance was apparently due to the enhancement of innate immune mechanisms that depend on alveolar macrophages.

"Such unique and unambiguous results demonstrate the great potential of GM-CSF and may be the remedy for a critical public health priority: developing strategies to reduce the morbidity and mortality from influenza,” said senior author Dr. Homayoun Shams, professor of pulmonary and infectious diseases at the University of Texas Health Science Center. "Improved methods to protect against influenza are sorely needed, particularly in the face of an impending pandemic. Development of such methods hinges on understanding host mechanisms that confer robust protection against influenza. Despite the widespread use of vaccines, influenza causes significant morbidity and mortality throughout the world, and those with poor immune systems are particularly more susceptible—such as very young, elderly, or immunocompromised individuals.”

"Unlike a vaccine, GM-CSF does not rely heavily on the body's ability to mount an immune counter-attack against a specific antigen or virus strain, but enhances the speed of local responses to virus infection and delicately balances the host immune responses," said Dr. Shams.

Related Links:
University of Texas Health Science Center




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.